Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3

Diagnostic relevance of circulating biomarkers in patients with lung cancer

(2017) Rafael Molina et al.   Cancer Biomarkers

S3-Leitlinie zum exokrinen Pankreaskarzinom

(2016) T. Seufferlein et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab

(2014) Shubham Pant et al.   CANCER

Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer

(2013) S Boeck et al.   BRITISH JOURNAL OF CANCER

Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy

(2013) Michael Haas et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer

(2012) P Kelly et al.   BRITISH JOURNAL OF CANCER

Systemic treatment of advanced pancreatic cancer

(2012) Volker Heinemann et al.   CANCER TREATMENT REVIEWS

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

(2012) Volker Heinemann et al.   GUT

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304

(2012) Martin J. Edelman et al.   Journal of Thoracic Oncology

Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)

(2011) E. Aranda et al.   ANNALS OF ONCOLOGY

Pancreatic cancer

(2011) Audrey Vincent et al.   LANCET

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ultraviolet B Irradiance and Vitamin D Status are Inversely Associated With Incidence Rates of Pancreatic Cancer Worldwide

(2010) Sharif B. Mohr et al.   PANCREAS

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report

(2009) M. J. Duffy et al.   ANNALS OF ONCOLOGY

Modelling prognostic factors in advanced pancreatic cancer

(2008) D D Stocken et al.   BRITISH JOURNAL OF CANCER

Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer

(2008) C. D. Blanke et al.   INVESTIGATIONAL NEW DRUGS

Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy

(2008) T. Tanaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

(2008) Viviane Hess et al.   LANCET ONCOLOGY

Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer

(2008) Stefan Holdenrieder et al.   LUNG CANCER

Improved Diagnosis of Pancreatic Adenocarcinoma Using Haptoglobin and Serum Amyloid A in a Panel Screen

(2008) Matthew A. Firpo et al.   WORLD JOURNAL OF SURGERY

Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine

(2006) Akira Sawaki et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY